MRTX-849 manufacturers
- MRTX-849
-
- $0.00 / 100g
-
2023-11-03
- CAS:2326521-71-3
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100000tons
- MRTX-849
-
- $50.00 / 1kg
-
2023-08-18
- CAS:2326521-71-3
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000tons
- MRTX-849
-
- $0.00 / 25KG
-
2023-08-13
- CAS:2326521-71-3
- Min. Order: 1KG
- Purity: 98%~99%
- Supply Ability: 20 T each week
|
| | MRTX-849 Basic information |
| Product Name: | MRTX-849 | | Synonyms: | MRTX849(Adagrasib);Adagrasib/MRTX-849;4-[7-(8-CHLORO-1-NAPHTHALENYL)-5,6,7,8-TETRAHYDRO-2-[[(2S)-1-METHYL-2-PYRR;MRTX-849;MRTX849;MRTX-849;MRTX 849;2-PIPERAZINEACETONITRILE, 4-[7-(8-CHLORO-1-NAPHTHALENYL)-5,6,7,8-TETRAHYDRO-2-[[(2S)-1-METHYL-2-PYRR;2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-;2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile | | CAS: | 2326521-71-3 | | MF: | C32H35ClFN7O2 | | MW: | 604.12 | | EINECS: | | | Product Categories: | api;2326521-71-3 | | Mol File: | 2326521-71-3.mol |  |
| | MRTX-849 Chemical Properties |
| Boiling point | 860.2±75.0 °C(Predicted) | | density | 1.295±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO:1.0(Max Conc. mg/mL);1.7(Max Conc. mM) | | form | A crystalline solid | | pka | 9.31±0.40(Predicted) |
| | MRTX-849 Usage And Synthesis |
| Uses | MRTX 849 is used as combination therapy for treatment of cancer. | | Brand name | Krazati | | General Description | Class: non-kinase;
Treatment: KRAS(G12C) NSCLC;
Other name: MRTX849;
Elimination half-life: 24 h;
Protein binding = 98.3% | | Mechanism of action | Adagrasib selectively modified mutant cysteine 12 in GDP-bound G12C and inhibited KRASdependent signaling. | | Clinical Use | Adagrasib is an irreversible inhibitor of the RAS GTPase family. It is approved by the FDA for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been identified by testing as having a KRAS (G12C) mutation. | | target | Primary target: KRAS(G12C) | | storage | Store at -20°C |
| | MRTX-849 Preparation Products And Raw materials |
|